Renovaro Inc. (NASDAQ:RENB) Short Interest Update

Renovaro Inc. (NASDAQ:RENB) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 5,060,000 shares, a growth of 30.7% from the December 15th total of 3,870,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 6.6% of the shares of the stock are short sold.

Renovaro Stock Performance

Shares of NASDAQ:RENB traded down $0.04 during trading hours on Friday, hitting $0.71. 624,909 shares of the company’s stock traded hands, compared to its average volume of 1,725,119. The company has a market cap of $112.22 million, a price-to-earnings ratio of -0.74 and a beta of 0.66. Renovaro has a 52 week low of $0.40 and a 52 week high of $5.25. The company’s fifty day simple moving average is $0.99 and its two-hundred day simple moving average is $0.84.

Hedge Funds Weigh In On Renovaro

Hedge funds have recently modified their holdings of the stock. Barclays PLC raised its holdings in Renovaro by 315.7% during the 3rd quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after buying an additional 52,804 shares during the period. State Street Corp increased its position in shares of Renovaro by 3.8% in the third quarter. State Street Corp now owns 1,323,832 shares of the company’s stock worth $640,000 after acquiring an additional 48,114 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Renovaro in the second quarter worth approximately $220,000. Rhumbline Advisers acquired a new stake in shares of Renovaro during the second quarter valued at approximately $79,000. Finally, SG Americas Securities LLC lifted its position in shares of Renovaro by 193.3% in the 4th quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock valued at $43,000 after acquiring an additional 34,090 shares in the last quarter. 71.41% of the stock is currently owned by institutional investors and hedge funds.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.